AbbVie Sponsors New BioLabs Facility in Toronto

Dow Jones

Apr 21

By Christopher Kuo

AbbVie is sponsoring BioLabs's new 40,000 square-foot lab and office facility in Toronto.

The biopharmaceutical company said Monday that it has agreed to become the founding sponsor of BioLabs University of Toronto to accelerate life sciences research. The facility will be a fully equipped laboratory and collaboration space for up to 30 early stage biotechnology startups, AbbVie said.

As part of its partnership with BioLabs, AbbVie will also offer an annual innovators award to an early stage biotech recipient, granting them mentorship and a year of laboratory and office space, the company said.

"This new facility will help provide Canadian biotech entrepreneurs with the infrastructure, mentorship and collaborative environment needed to translate promising science into real-world health solutions," said Christian Schubert, vice president and global head of AbbVie.

Write to Christopher Kuo at chris.kuo@wsj.com

(END) Dow Jones Newswires

Christian Schubert is vice president and global head of AbbVie Ventures. "AbbVie Sponsors New BioLabs Facility in Toronto," published at 3:25 p.m. ET on April 20, misstated his title.

(END) Dow Jones Newswires

April 21, 2026 12:02 ET (16:02 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/2629773481"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2629773481\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2629773481?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-21 03:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2629773481","market":"sh","top_or_hot":-1,"title":"AbbVie Sponsors New BioLabs Facility in Toronto","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Christopher Kuo \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  AbbVie is sponsoring BioLabs's new 40,000 square-foot lab and office facility in Toronto. \n</p>\n<p>\n  The biopharmaceutical company said Monday that it has agreed to become the founding sponsor of BioLabs University of Toronto to accelerate life sciences research. The facility will be a fully equipped laboratory and collaboration space for up to 30 early stage biotechnology startups, AbbVie said. \n</p>\n<p>\n  As part of its partnership with BioLabs, AbbVie will also offer an annual innovators award to an early stage biotech recipient, granting them mentorship and a year of laboratory and office space, the company said. \n</p>\n<p>\n  \"This new facility will help provide Canadian biotech entrepreneurs with the infrastructure, mentorship and collaborative environment needed to translate promising science into real-world health solutions,\" said Christian Schubert, vice president and global head of AbbVie. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Christopher Kuo at chris.kuo@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n</font><font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Christian Schubert is vice president and global head of AbbVie Ventures. \"AbbVie Sponsors New BioLabs Facility in Toronto,\" published at 3:25 p.m. ET on April 20, misstated his title. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 21, 2026 12:02 ET (16:02 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AbbVie Sponsors New BioLabs Facility in Toronto</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAbbVie Sponsors New BioLabs Facility in Toronto\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-04-21 03:25</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Christopher Kuo \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  AbbVie is sponsoring BioLabs's new 40,000 square-foot lab and office facility in Toronto. \n</p>\n<p>\n  The biopharmaceutical company said Monday that it has agreed to become the founding sponsor of BioLabs University of Toronto to accelerate life sciences research. The facility will be a fully equipped laboratory and collaboration space for up to 30 early stage biotechnology startups, AbbVie said. \n</p>\n<p>\n  As part of its partnership with BioLabs, AbbVie will also offer an annual innovators award to an early stage biotech recipient, granting them mentorship and a year of laboratory and office space, the company said. \n</p>\n<p>\n  \"This new facility will help provide Canadian biotech entrepreneurs with the infrastructure, mentorship and collaborative environment needed to translate promising science into real-world health solutions,\" said Christian Schubert, vice president and global head of AbbVie. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Christopher Kuo at chris.kuo@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n</font><font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Christian Schubert is vice president and global head of AbbVie Ventures. \"AbbVie Sponsors New BioLabs Facility in Toronto,\" published at 3:25 p.m. ET on April 20, misstated his title. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 21, 2026 12:02 ET (16:02 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2357627491.SGD","symbol_name":"TRP GLOBAL VALUE EQUITY \"AH\" (SGDHDG) ACC","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2629773481","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2629773481","pubTimestamp":1776713100,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"AbbVie is sponsoring BioLabs's new 40,000 square-foot lab and office facility in Toronto.The biopharmaceutical company said Monday that it has agreed to become the founding sponsor of BioLabs University of Toronto to accelerate life sciences research. The facility will be a fully equipped laboratory and collaboration space for up to 30 early stage biotechnology startups, AbbVie said.As part of its partnership with BioLabs, AbbVie will also offer an annual innovators award to an early stage biotech recipient, granting them mentorship and a year of laboratory and office space, the company said.\"This new facility will help provide Canadian biotech entrepreneurs with the infrastructure, mentorship and collaborative environment needed to translate promising science into real-world health solutions,\" said Christian Schubert, vice president and global head of AbbVie.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2357627491.SGD":"TRP GLOBAL VALUE EQUITY \"AH\" (SGDHDG) ACC","IE00B42XCP33.USD":"GUINNESS GLOBAL EQUITY INCOME \"C\" (USD) INC","LU2133065610.SGD":"JPMorgan Investment Funds - Global Dividend A (mth) SGD","LU0069063385.USD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"A\" (USD) ACC","IE000MB6IJN5.SGD":"RQI GLOBAL \"I\" (SGD) ACC","LU0545039389.USD":"BGF GLOBAL EQUITY INCOME \"A2\" ACC","ABBV":"艾伯维公司","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","LU0689626769.HKD":"AB SICAV I - SUSTAINABLE US THEMATIC PORTFOLIO \"A\" (HKD) ACC","LU0211328371.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (MDIS) (USD)   INC","LU1162221912.USD":"FRANKLIN INCOME \"A\" (USD) ACC","BK4534":"瑞士信贷持仓","BK4198":"医疗保健用品","AIDX":"20/20 BIOLABS INC","SG9999011175.SGD":"Nikko AM Global Dividend Equity Dis SGD-H","SG9999003800.SGD":"Nikko AM Global Dividend Equity Acc SGD-H","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","LU0256863902.USD":"ALLIANZ US EQUITY \"AT\" (USD) ACC","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","LU0203347892.USD":"SCHRODER ISF QEP GLOBAL ACTIVE VALLUE \"A\" (USD)  INC AV","BK4581":"高盛持仓","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","BK4566":"资本集团","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","IE0004445239.USD":"JANUS HENDERSON US FORTY \"A2\" (USD) ACC","LU0058720904.USD":"联博国际健康护理基金A","SG9999015945.SGD":"LionGlobal Disruptive Innovation Fund A SGD","LU0965509010.AUD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (AUDHDG) INC","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","SG9999015986.USD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (USD) ACC","LU2237443549.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA SGD-H","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","LU1989772923.USD":"CPR Invest - Climate Action A2 Acc USD-H","LU1496350171.SGD":"FRANKLIN DIVERSIFIED BALANCED \"A\" (SGDHDG) ACC","LU0098860793.USD":"FRANKLIN INCOME \"A\" INC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU1934455277.USD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"AD\" (USD) INC","LU2089283258.USD":"安联环球可持续基金Cl AM Dis","LU0310799852.SGD":"FTIF - Templeton Global Equity Income A MDIS SGD","IE0000B7K699.USD":"RQI GLOBAL \"I\" (USD) INC","LU0320765646.SGD":"FTIF - Franklin Income A MDIS SGD-H1","LU1934455194.USD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"A\" (USD) ACC","LU1839511570.USD":"WELLS FARGO GLOBAL FACTOR ENHANCED EQUITY \"I\" (USD) ACC","IE00B3PB1722.GBP":"GUINNESS GLOBAL EQUITY INCOME \"C\" (GBP) INC","LU0912757837.SGD":"JPMorgan Investment Funds - Global Income A (mth) SGD-H","IE00BDGV0183.EUR":"GUINNESS GLOBAL EQUITY INCOME \"C\" (EUR) INC"},"translate_title":"艾伯维赞助多伦多新生物实验室设施","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABBV":1.5,"AIDX":0.9},"content_text":"By Christopher Kuo \n\n\n \n\n\n  AbbVie is sponsoring BioLabs's new 40,000 square-foot lab and office facility in Toronto. \n\n\n  The biopharmaceutical company said Monday that it has agreed to become the founding sponsor of BioLabs University of Toronto to accelerate life sciences research. The facility will be a fully equipped laboratory and collaboration space for up to 30 early stage biotechnology startups, AbbVie said. \n\n\n  As part of its partnership with BioLabs, AbbVie will also offer an annual innovators award to an early stage biotech recipient, granting them mentorship and a year of laboratory and office space, the company said. \n\n\n  \"This new facility will help provide Canadian biotech entrepreneurs with the infrastructure, mentorship and collaborative environment needed to translate promising science into real-world health solutions,\" said Christian Schubert, vice president and global head of AbbVie. \n\n\n \n\n\n  Write to Christopher Kuo at chris.kuo@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n\n \n\n\n  Christian Schubert is vice president and global head of AbbVie Ventures. \"AbbVie Sponsors New BioLabs Facility in Toronto,\" published at 3:25 p.m. ET on April 20, misstated his title. \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 21, 2026 12:02 ET (16:02 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}